Literature DB >> 23620150

Intratympanic dexamethasone injection for refractory tinnitus: prospective placebo-controlled study.

Seong Jun Choi1, Jong Bin Lee, Hye Jin Lim, Seung Min In, Jong-Yeup Kim, Kyung Hee Bae, Yun-Hoon Choung.   

Abstract

OBJECTIVES/HYPOTHESIS: The purpose of this study is to investigate the effectiveness of intratympanic dexamethasone injections (ITDI) for refractory tinnitus. STUDY
DESIGN: A prospective, placebo-controlled, randomized, double-blind study.
METHODS: Thirty patients with refractory tinnitus who were diagnosed in the Department of Otolaryngology, Ajou University Hospital, Suwon, Republic of Korea, between 2006 and 2007 were enrolled and then were assigned into two groups of ITDI (15 patients) or saline (15 patients) by permuted block randomization. Intratympanic injections were double-blind performed four times within 2 weeks. After 4 weeks, we analyzed the improvement and aggravation rates of tinnitus using the following parameters: questionnaires, tinnitus handicap index (THI), loudness matching test, frequency, and duration of tinnitus.
RESULTS: The effectiveness rates of ITDI for refractory tinnitus reported in the tinnitus questionnaires, in the THI, and in the loudness matching test were all 33.3% in the steroid group, and 26.7%, 40.0%, and 26.7% in the saline group, respectively. However, there were no statistically significant differences in both groups. To analyze the therapeutic effect of ITDI on tinnitus under 6 months of its development, the improvement rates reported in the tinnitus questionnaires, in the THI, and in the loudness matching test were all 28.5% in the steroid group, and 40.0%, 40.0%, and 30.0% in the saline group, respectively. There were also no statistically significant differences in both groups.
CONCLUSIONS: ITDI may not be effective for refractory tinnitus. The indication of ITDI for tinnitus needs to be limited to specific cases.
Copyright © 2013 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Tinnitus; dexamethasone; injection; refractory; treatment

Mesh:

Substances:

Year:  2013        PMID: 23620150     DOI: 10.1002/lary.24126

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  7 in total

Review 1.  Evidence and evidence gaps in tinnitus therapy.

Authors:  Gerhard Hesse
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2016-12-15

Review 2.  Intratympanic corticosteroids injections: a systematic review of literature.

Authors:  Philippe Lavigne; François Lavigne; Issam Saliba
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-23       Impact factor: 2.503

3.  Predictive Factors for the Success of Intratympanic Dexamethasone Treatment of Acute Subjective Tinnitus.

Authors:  Hyeon Sik Oh; Eun Sub Lee; Yong-Hwi An; Hyun Joon Shim
Journal:  J Int Adv Otol       Date:  2020-12       Impact factor: 1.017

Review 4.  A multidisciplinary systematic review of the treatment for chronic idiopathic tinnitus.

Authors:  Hans-Peter Zenner; Wolfgang Delb; Birgit Kröner-Herwig; Burkhard Jäger; Ingrid Peroz; Gerhard Hesse; Birgit Mazurek; Gerhard Goebel; Christian Gerloff; Regina Trollmann; Eberhard Biesinger; Harald Seidler; Berthold Langguth
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-19       Impact factor: 2.503

5.  The Efficacy of Intratympanic Steroid Injection in Tinnitus Cases Unresponsive to Medical Treatment.

Authors:  Haydar Murat Yener; Elif Sarı; Mehmet Aslan; Umur Yollu; Emine Deniz Gözen; Ender İnci
Journal:  J Int Adv Otol       Date:  2020-08       Impact factor: 1.017

6.  Intratympanic Steroid for the Management of Sudden Hearing Loss: Introduction of a Tapering Method.

Authors:  Mohsen Rajati; Mohammad Mehdi Ghasemi; Mohammad-Reza Sharifian; Navid Nourizadeh; Razieh Yousefi; Masoumeh Hosseinpoor
Journal:  Iran J Otorhinolaryngol       Date:  2022-01

7.  Effectiveness of Intratympanic Dexamethasone Injection for Tinnitus Treatment: A Systematic Review and Meta-Analysis.

Authors:  Juyong Chung; Doh Young Lee; Jong Seung Kim; Young Ho Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2022-02-12       Impact factor: 3.372

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.